Search

Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.

… Thursday, March 22, 2012 Memorial Sloan Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide  medical professionals with improved access to current and comprehensive cancer data and practices. The

… Wednesday, January 5, 2022 The oral menin inhibitor SNDX-5613 (Syndax Pharmaceuticals) demonstrated promising antileukemic activity and an acceptable safety profile in patients with heavily pretreated acute leukemias with specific genetic mutations, according to results from phase 1 of the AUGMENT-101

Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.

… Wednesday, February 15, 2012 Summary Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer. Researchers from Memorial Sloan Kettering have published two studies that provide clues about genetic mutations that

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

… Wednesday, May 25, 2011 An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute

A drug was shown to improve outcomes in women with HER2-positive early breast cancer when added to standard therapy.

… Monday, June 5, 2017 Summary Women with HER2-positive breast cancer typically receive drugs that block the HER2 protein combined with chemotherapy. A large clinical trial shows that pertuzumab reduces the risk of recurrence in certain women with breast cancer. Update: On December 20, 2017 the FDA approved

Read about how Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial "glass ceiling."

… Thursday, July 15, 2021 Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial “glass ceiling.” The Memorial Sloan Kettering radiation experts were contributors to a https://www.nap.edu/read/26155/chapter/1 new report

Craig B. Thompson, MD, President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50.

… Tuesday, August 3, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50 . The list recognizes the most notable individuals who are making strides in the life sciences in New York, including leaders

Get helpful advice on being a caregiver for someone with cancer.

… Thursday, August 19, 2021 Cancer caregivers wear many hats: chauffer, secretary, chef, cheerleader, and more. It’s no wonder the position can feel overwhelming. “It’s a role you never applied for and probably never trained for either,” says Diane Reidy-Lagunes, a medical oncologist at Memorial Sloan

Memorial Sloan Kettering Cancer Center (MSK) has appointed Atefeh “Atti” Riazi as Chief Information Officer (CIO). In this role, Ms. Riazi will develop and implement an enterprise-wide, long-term strategic information technology (IT) plan and oversee the integration of data and technology resources across the organization.

… Thursday, January 30, 2020 Atefeh Riazi Atefeh Riazi Memorial Sloan Kettering Cancer Center (MSK) has appointed Atefeh “Atti” Riazi as Chief Information Officer (CIO), effective February 3. In this role, Ms. Riazi will develop and implement an enterprise-wide, long-term strategic information technology

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, January 4, 2024 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Omar Abdel-Wahab Received the William Dameshek Prize from the American Society of Hematology Omar Abdel-Wahab, MD , leukemia specialist, Chair of the Molecular Pharmacology at the